Trajectories of health-related quality of life and fatigue during vedolizumab therapy in inflammatory bowel disease.

Casper SteenholdtRuben Due LorentsenPernille Nørgaard PetersenJørn Brynskov

Published in: Journal of gastroenterology and hepatology (2022)

QoL rapidly improves and predicts later significant clinical-objective efficacies of vedolizumab at end of induction and 1 year. Fatigue improves slowly after remission is attained.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
sleep quality
depressive symptoms
disease activity
stem cells
rheumatoid arthritis
bone marrow
physical activity
replacement therapy